Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
NCT ID: NCT00195572
Last Updated: 2009-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
200 participants
INTERVENTIONAL
2002-05-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
NCT00209664
Study of S-1 Plus LV for Advanced Gastric Cancer
NCT02090153
Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
NCT00209638
Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
NCT00503321
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Isovorin
TS-1
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal organ function of bone marrow, heart, liver and kidney
* Age of 20-77
Other inclusion applies
Exclusion Criteria
* Ongoing administration of flucytosine
* Pregnant or breastfeeding women
Other exclusion applies
20 Years
77 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Adachi-ku, Tokyo, , Japan
Anjo, , Japan
Aomori, , Japan
Chiba, , Japan
Chiba, , Japan
Chikushino-shi, , Japan
Fukuoka, , Japan
Fukuroi-shi, , Japan
Funai-gun, , Japan
Hiroshima, , Japan
Hiroshima, , Japan
Ichihara-shi, , Japan
Kanagawa, , Japan
Kanazawa, , Japan
Kisaradu-shi, , Japan
Kitaadachi-gun, , Japan
Koto-ku, Tokyo, , Japan
Kyoto, , Japan
Misawa-shi, , Japan
Morioka, , Japan
Nagasaki, , Japan
Nagoya, , Japan
Nagoya, , Japan
Osaka, , Japan
Osaka, , Japan
Ōmura, , Japan
Saga, , Japan
Sagamiharashi, , Japan
Sapparo City, , Japan
Sapporo, , Japan
Sapporo, , Japan
Sapporo, , Japan
Sasebo-shi, , Japan
Sendai, , Japan
Sendai, , Japan
Shizuka, , Japan
Shizuoka, , Japan
Sizuoka-shi, , Japan
Takatuki-si, , Japan
Tsuchiura-shi, , Japan
Tsukuba, , Japan
Uji-shi, , Japan
Yamagata, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ISO/5FU-10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.